Email this article Taxanes in adjuvant and neoadjuvant therapy for breast cancer
- Authors: Limareva S.V.1
-
Affiliations:
- Department of Chemotherapy, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
- Issue: No 4 (2010)
- Pages: 15-23
- Section: MAMMOLOGY. TREATMENT
- Published: 29.11.2010
- URL: https://ojrs.abvpress.ru/ojrs/article/view/263
- DOI: https://doi.org/10.17650/1994-4098-2010-0-4-15-23
- ID: 263
Cite item
Full Text
Abstract
Taxanes (paclitaxel and docetaxel) are currently considered to be basic cytostatics in the treatment of all breast cancer (BC) stages. The results of conducted and ongoing clinical trials suggest that incorporation of taxanes into adjuvant and neoadjuvant chemotherapy regimens enhances the efficiency of treatment for operable BC and show it necessary to apply an individual approach depending on prognostic and predictive factors.
About the authors
S. V. Limareva
Department of Chemotherapy, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Author for correspondence.
Email: s-limareva@yandex.ru
Russian Federation
References
Supplementary files
